Literature DB >> 3567051

Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients.

D J Edwards, J E Axelson, J P Visco, S vanEvery, R L Slaughter, D Lalka.   

Abstract

The urinary metabolite profile of quinidine and the oral clearance of this drug were studied under steady state conditions in five smoking and nine non-smoking patients. No significant differences were observed in the urinary recovery of unchanged quinidine, 3S-3-hydroxyquinidine, 2'-oxoquinidinone or quinidine-N-oxide between smokers and non-smokers. In addition, the plasma clearance of quinidine was not affected by the smoking status of subjects. These results suggest that cigarette smoke does not induce any of the main pathways for quinidine metabolism in a typical patient population and that the consideration of smoking status is of little utility in aiding in the selection of initial dosage regimens for this drug.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3567051      PMCID: PMC1386236          DOI: 10.1111/j.1365-2125.1987.tb03057.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Interaction of quinidine with anticonvulsant drugs.

Authors:  J L Data; G R Wilkinson; A S Nies
Journal:  N Engl J Med       Date:  1976-03-25       Impact factor: 91.245

2.  Specific determination of quinidine and (3S)-3-hydroxyquinidine in human serum by high-pressure liquid chromatography.

Authors:  D E Drayer; K Restivo; M M Reidenberg
Journal:  J Lab Clin Med       Date:  1977-11

Review 3.  Role of tobacco smoking in pharmacokinetics.

Authors:  W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1978-02

4.  Impaired enzyme induction by rifampicin in the elderly.

Authors:  Y Twum-Barima; T Finnigan; A I Habash; R D Cape; S G Carruthers
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

5.  Quinidine-rifampin interaction.

Authors:  Y Twum-Barima; S G Carruthers
Journal:  N Engl J Med       Date:  1981-06-11       Impact factor: 91.245

6.  Disposition kinetics of quinidine.

Authors:  C T Ueda; D S Hirschfeld; M M Scheinman; M Rowland; B J Williamson; B S Dzindzio
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

7.  Quinidine therapy in hospitalized patients with ventricular arrhythmias.

Authors:  N H Carliner; W G Crouthamel; M L Fisher; M A Mugmon; D L Vassar; P K Narang; G D Plotnick
Journal:  Am Heart J       Date:  1979-12       Impact factor: 4.749

Review 8.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

9.  Relation of ventricular premature beat suppression to serum quinidine concentraton determined by a new and specific assay.

Authors:  N H Carliner; M L Fisher; W G Crouthamel; P K Narang; G D Plotnick
Journal:  Am Heart J       Date:  1980-10       Impact factor: 4.749

  9 in total
  4 in total

1.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to alpha 1-acid glycoprotein (AGP).

Authors:  J A Barnett; D E Brenner; P J Creaven; D Lalka
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

Review 3.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

4.  Cigarette smoking enhances the elimination of quinine.

Authors:  S Wanwimolruk; S M Wong; P F Coville; S Viriyayudhakorn; S Thitiarchakul
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.